In a filing, Ocular Therapeutix Inc revealed its Officer PETER KAZUO KAISER acquired Company’s shares for reported $20684.0 on Feb 24 ’25. In the deal valued at $6.87 per share,3,009 shares were bought.
Then, JEFFREY S. HEIER bought 3,061 shares, generating $21,043 in total proceeds.
Before that, PRAVIN DUGEL bought 21,475 shares. Ocular Therapeutix Inc shares valued at $147,617 were divested by the Officer at a price of $6.87 per share.
Scotiabank initiated its Ocular Therapeutix Inc [OCUL] rating to a Sector outperform in a research note published recently. A number of analysts have revised their coverage, including TD Cowen’s analysts, who increased its forecast for the stock in mid June from “a Hold” to “a Buy”. BofA Securities started covering the stock on February 09, 2024. It rated OCUL as “a Buy”.
Price Performance Review of OCUL
On Tuesday, Ocular Therapeutix Inc [NASDAQ:OCUL] saw its stock jump 0.59% to $6.77. Over the last five days, the stock has lost -5.97%. Ocular Therapeutix Inc shares have fallen nearly -20.73% since the year began. Nevertheless, the stocks have fallen -30.21% over the past one year. While a 52-week high of $11.77 was reached on 01/07/25, a 52-week low of $4.06 was recorded on 02/25/25. SMA at 50 days reached $8.06, while 200 days put it at $8.22.
Levels Of Support And Resistance For OCUL Stock
The 24-hour chart illustrates a support level at 6.64, which if violated will result in even more drops to 6.51. On the upside, there is a resistance level at 6.91. A further resistance level may holdings at 7.05. The Relative Strength Index (RSI) on the 14-day chart is 29.43, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.50, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.77%. Stochastics %K at 3.28% indicates the stock is a buying.
The most recent change occurred on April 21, 2023 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $18 price target.
